219 related articles for article (PubMed ID: 26606072)
1. Conversion to Once-Daily Tacrolimus Results in Increased p38MAPK Phosphorylation in T Lymphocytes of Kidney Transplant Recipients.
Kannegieter NM; Shuker N; Vafadari R; Weimar W; Hesselink DA; Baan CC
Ther Drug Monit; 2016 Apr; 38(2):280-4. PubMed ID: 26606072
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation.
Kannegieter NM; Hesselink DA; Dieterich M; de Graav GN; Kraaijeveld R; Rowshani AT; Leenen PJM; Baan CC
Ther Drug Monit; 2017 Oct; 39(5):463-471. PubMed ID: 28640063
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry.
Vafadari R; Hesselink DA; Cadogan MM; Weimar W; Baan CC
Transplantation; 2012 Jun; 93(12):1245-51. PubMed ID: 22643331
[TBL] [Abstract][Full Text] [Related]
4. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
[TBL] [Abstract][Full Text] [Related]
5. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
6. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
Kim SH; Lee SD; Kim YK; Park SJ
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
[TBL] [Abstract][Full Text] [Related]
7. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients.
Ruangkanchanasetr P; Sanohdontree N; Supaporn T; Sathavarodom N; Satirapoj B
Ann Transplant; 2016 Dec; 21():765-774. PubMed ID: 27980321
[TBL] [Abstract][Full Text] [Related]
8. Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study.
Sukkha S; Chindavijak B; Montakantikul P; Ingsathit A; Nosoongnoen W; Sumethkul V
Int J Clin Pharm; 2017 Dec; 39(6):1298-1303. PubMed ID: 29101615
[TBL] [Abstract][Full Text] [Related]
9. Trough Level and Tacrolimus Variability of Early Converted Once-Daily Tacrolimus: 1-Year Follow-up Study.
Sukkha S; Suansanae T; Iamrahong P; Wiwattanathum P
Transplant Proc; 2020 Apr; 52(3):775-779. PubMed ID: 32143870
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen.
Meçule A; Tinti F; Bachetoni A; Poli L; D'Alessandro M; Alessandri C; Umbro I; Nofroni I; Berloco PB; Mitterhofer AP
Transplant Proc; 2011 May; 43(4):1017-9. PubMed ID: 21620040
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant Tacrolimus Dose Requirements Predict Early Posttransplant Dose Requirements in Blood Group AB0-Incompatible Kidney Transplant Recipients.
Shuker N; de Man FM; de Weerd AE; van Agteren M; Weimar W; Betjes MG; van Gelder T; Hesselink DA
Ther Drug Monit; 2016 Apr; 38(2):217-22. PubMed ID: 26630539
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
Meçule A; Tinti F; Poli L; Bachetoni A; Umbro I; Nofroni I; Lai Q; Pretagostini R; Berloco PB; Mitterhofer AP
Transplant Proc; 2011 May; 43(4):1024-7. PubMed ID: 21620042
[TBL] [Abstract][Full Text] [Related]
13. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation.
Kolonko A; Chudek J; Wiecek A
Transplant Proc; 2011 Oct; 43(8):2950-3. PubMed ID: 21996198
[TBL] [Abstract][Full Text] [Related]
14. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism.
Uchida J; Kuwabara N; Machida Y; Iwai T; Naganuma T; Kumada N; Nakatani T
Transplant Proc; 2012 Jan; 44(1):128-33. PubMed ID: 22310596
[TBL] [Abstract][Full Text] [Related]
15. Effects of conversion from a twice-daily tacrolimus to a once-daily tacrolimus on glucose metabolism in stable kidney transplant recipients.
Uchida J; Iwai T; Kabei K; Machida Y; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transplant Proc; 2014; 46(2):532-6. PubMed ID: 24656005
[TBL] [Abstract][Full Text] [Related]
16. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.
de Jonge H; Kuypers DR; Verbeke K; Vanrenterghem Y
Transplantation; 2010 Sep; 90(5):523-9. PubMed ID: 20592652
[TBL] [Abstract][Full Text] [Related]
17. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
[TBL] [Abstract][Full Text] [Related]
18. Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial.
Kannegieter NM; Hesselink DA; Dieterich M; de Graav GN; Kraaijeveld R; Baan CC
Sci Rep; 2017 Nov; 7(1):15135. PubMed ID: 29123208
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
20. The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients.
Sukkha S; Chindavijak B; Nosoongnoen W; Phakdeekitchareon B; Kitiyakara C; Sumethkul V
Drug Metab Pharmacokinet; 2020 Feb; 35(1):139-144. PubMed ID: 31727575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
